Results 131 to 140 of about 4,153 (212)

Finerenone is associated with pronounced uric acid reduction in hyperuricemic diabetic kidney disease: a real-world analysis. [PDF]

Front Pharmacol
Lin Y, Tian J, Du K, Liu B.
europepmc   +1 more source

Reductions in myocardial interstitial fibrosis are dissociated from LV chamber stiffness in swine with repetitive pressure overload. [PDF]

Am J Physiol Heart Circ Physiol
Hudson E, Gilligan A, Canty JM, Weil BR.
europepmc   +1 more source

A retrospective cohort study on the impact of finerenone on the hepatic fibrosis indicator FIB-4. [PDF]

Front Endocrinol (Lausanne)
An B, Chen F, An W, Cui Z, Jiang L, Zhou S, Song M, Huang W, Yan H.   +8 more
europepmc   +1 more source

Finerenone for diabetic hearts: a critical appraisal of MACE benefits and the research road ahead. [PDF]

Eur Heart J Cardiovasc Pharmacother
Dong W, Li D, Zhao J.
europepmc   +1 more source

Effect of finerenone on renal function in patients with type 2 diabetic nephropathy: a retrospective cohort study. [PDF]

Front Endocrinol (Lausanne)
Liu XY, Zhao YM, Zhang YG, Liu Y, Wang BY, Hao ZZ, Hu MH.   +6 more
europepmc   +1 more source

Dissecting the role of mineralocorticoid receptors in binge-like alcohol drinking in mice: Finerenone as a potential pharmacotherapy. [PDF]

Psychopharmacology (Berl)
Wilkinson CS, Bruns N, Pince CL, McGinn MA, Farokhnia M, Leggio L, Vendruscolo LF.   +6 more
europepmc   +1 more source

Blinded Withdrawal of Finerenone After Long-Term Treatment in the FINEARTS-HF Trial [PDF]

Amarante, Flaviana, Claggett, Brian L., Desai, Akshay S., Glasauer, Andrea, Henderson, Alasdair D., Jhund, Pardeep S., Lam, Carolyn S.P., Lay-Flurrie, James, McMurray, John J.V., Pitt, Bertram, Senni, Michele, Shah, Sanjiv J., Solomon, Scott D., Udell, Jacob A., Vaduganathan, Muthiah, Voors, Adriaan A., Zannad, Faiez   +16 more
core   +1 more source

Efficacy and Safety of Finerenone Combined with Dapagliflozin in the Treatment of Non-Diabetic Chronic Kidney Disease: A Single-Center Retrospective Study. [PDF]

Drug Des Devel Ther
Ma J, Su Q, Wang H, Xu J, Yuan C, Fan G, Ying J, Bian X.   +7 more
europepmc   +1 more source

Efficacy and safety of finerenone in diabetic kidney disease: Latin American experience from FINDKDLATAM trial. [PDF]

World J Nephrol
Arnedo RD, Polo VS, Garcia JB, Gutiérrez JF, Clason ER, Domínguez D, Rebutti GM, Mancia CM, López RT, Meza MR, López DT, Muñoz Zambrano JJ, Herrera EL, Dina-Batlle E, Terrones MC, de Moraes TP, Yánez TR, Osorio W, Cabeza AA, Rico-Fontalvo J.   +19 more
europepmc   +1 more source

EMPEROR-Preserved Risk Model and Outcomes in the FINEARTS-HF Trial: A Prespecified Secondary Analysis of FINEARTS-HF.

JAMA Cardiol
Chimura M, McDowell K, Jhund PS, Henderson AD, Claggett BL, Desai AS, Brinker M, Lay-Flurrie J, Glasauer A, Goea L, Berger M, Lam CSP, Senni M, Voors AA, Zannad F, Pitt B, Vaduganathan M, Solomon SD, McMurray JJV.   +18 more
europepmc   +1 more source